Cardio Training for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cardio Training for Health & Longevity

Created on 09/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Sustained rhythmic movement raising breathing and heart rate. Trials show higher aerobic capacity, lower blood pressure, better blood sugar control, mood, sleep and thinking; higher fitness tracks fewer deaths. Costs are dose-shaped: overuse injury in beginners, irregular heart rhythm and more fatty deposits in heart arteries at very high volumes. (Full Review)

Protocol

Weekly structure
150–300 min, 3–5 sessions
One or two high-intensity; commonly paired with two resistance sessions
Polarised approach
80% easy / 20% hard
80% below the first lactate threshold, 20% near maximal
Session length and splitting
45–90 min base; 20–40 intervals
Accumulated short bouts appear comparable to single continuous sessions
Time to effect
Aerobic capacity
6–8 weeks
Measurable gains in maximal oxygen uptake
Blood pressure & HbA1c
8–12 weeks
Resting pressure and blood sugar fall
Mood
1–2 weeks
Alongside plasma volume expansion

Benefits

Contraindications
  • Myocardial infarction within 48 h; unstable angina
  • Acute myocarditis or pericarditis (3–6 months)
  • Decompensated heart failure (NYHA IV) until stable
  • Severe symptomatic aortic stenosis (under 1.0 cm²)
  • Uncontrolled symptomatic arrhythmia; untreated high-grade AV block
  • Resting blood pressure above 200/110 mmHg, until treated
  • Pulmonary embolism or deep vein thrombosis within 7 days
  • Acute febrile illness, or below-the-neck symptoms
  • Uncontrolled diabetes above 250 mg/dL with ketosis
  • Aortic dissection; aortic root above 45 mm in Marfan syndrome
    •
Key Interactions
  • Beta-blockers (metoprolol, bisoprolol, carvedilol)
  • Insulin and sulfonylureas (glipizide, glimepiride)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin)
  • Diuretics, renin-angiotensin blockers (furosemide, losartan)
  • Anticoagulants and antiplatelets (apixaban, warfarin)
  • QT-prolonging agents (amiodarone, sotalol, citalopram)
  • Non-steroidal anti-inflammatory drugs (ibuprofen)
  • Sedating antihistamines, decongestants (pseudoephedrine)
  • High-dose antioxidants (vitamin C above 1 g daily, vitamin E)
  • Beetroot nitrate, citrulline, other vasodilatory supplements
  • Creatine, caffeine and sodium bicarbonate
  • Concurrent resistance training
    •

Risk & Side Effects

  • High: Musculoskeletal overuse injury
    •
  • Medium: Transient rise in cardiac arrest risk during vigorous exertion; atrial fibrillation at high training volumes; higher coronary plaque in lifelong male endurance athletes; low energy availability; exertional heat illness; exercise-induced bronchoconstriction
  • Low: Attenuated fibre hypertrophy from concurrent training; exercise-associated hyponatremia; iron deficiency without anaemia
  • Speculative: Myocardial fibrosis from extreme endurance loads; oxidative damage from chronic high training loads

Monitoring

Marker Target Why
VO₂max Above the 75th percentile for age and sex Strongest single predictor of all-cause mortality
Resting heart rate 45–60 beats per minute Tracks vagal tone and training status
Heart rate variability Deviation from a rolling 7-day personal baseline Distinguishes productive training load from accumulated stress
Blood pressure 110–120 / 70–80 mmHg Primary vascular outcome of cardio training
HbA1c 4.8–5.4% Tracks glycaemic response to training volume
Fasting insulin 2–5 µIU/mL Detects insulin-sensitivity gains before HbA1c moves
hs-CRP Below 1.0 mg/L Tracks systemic inflammation and recovery status
Ferritin 50–150 ng/mL Detects iron deficiency that caps aerobic adaptation
ApoB Below 80 mg/dL, or below 60 mg/dL with existing plaque Best available marker of atherogenic particle burden
Lipoprotein(a) Below 30 mg/dL (75 nmol/L) Identifies inherited risk unmodified by training
Coronary artery calcium score 0 Agatston units Quantifies established coronary plaque before vigorous protocols
Testosterone (men) / cycle regularity (women) Total testosterone 500–800 ng/dL; regular ovulatory cycles Earliest marker of low energy availability

Cadence: Daily resting heart rate and variability; fitness retest 8–12 weeks then 6–12 monthly; blood panel annually; coronary calcium imaging 3–5 yearly

Qualitative Assessment

  • Session rating of perceived exertion at a fixed workload, falling as fitness rises
  • Recovery speed — heart rate drop in the first minute after effort, above 12 beats
  • Sleep onset latency and subjective sleep quality on training versus rest days
  • Daytime energy and motivation to train, where a sustained drop signals load
  • Everyday capacity — stairs, carrying, hill walking — without breathlessness
  • Mood stability and cognitive clarity, both of which degrade early in overreaching
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.